title: Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
abstract: The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months. The selection of an effective first-line treatment represents a crucial point in order to achieve good outcome results. In the last years, the intensive FOLFOXIRI regimen in combination with bevacizumab became a new standard option in this setting. In the present review we summarized the main steps of FOLFOXIRI regimen development from the first pilot study to the recent findings with biological agents, with a specific focus on practical aspects, such as patient's selection, adverse event management, treatment schedules and post-progression strategies. Possible predictive markers, open issues and ongoing clinical trials have been also deeply described.
authors: Division of Medical Oncology, Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa 2248-503, Japan; Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States. Electronic address: y.suna0825@gmail.com.
authors: Yu
authors: Y
authors: Sunakawa
authors: Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States; U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa 56126, Italy.
authors: Marta
authors: M
authors: Schirripa
authors: Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States.
authors: Heinz-Josef
authors: HJ
authors: Lenz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000032:analysis; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D060046:Maintenance Chemotherapy; D020360:Neoadjuvant Therapy / Q000379:methods; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Anti-EGFR; Bevacizumab; FOLFOXIRI; First-line; Metastatic colorectal cancer